Lexicon Pharmaceuticals’ (LXRX) Buy Rating Reaffirmed at Wedbush

Wedbush reaffirmed their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report released on Monday, TipRanks reports. The brokerage currently has a $10.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on LXRX. ValuEngine downgraded shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research report on Tuesday, March 3rd. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, March 6th. G.Research downgraded shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, December 11th. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, March 12th. Finally, Gabelli downgraded shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, December 11th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. Lexicon Pharmaceuticals has a consensus rating of Hold and an average target price of $4.70.

Shares of LXRX stock opened at $1.95 on Monday. Lexicon Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $7.27. The company has a debt-to-equity ratio of 2.00, a quick ratio of 5.10 and a current ratio of 5.17. The company has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $3.39. The company has a market capitalization of $210.73 million, a price-to-earnings ratio of 1.88 and a beta of 1.12.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.77) by $0.29. Lexicon Pharmaceuticals had a net margin of 40.40% and a return on equity of 303.98%. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $10.59 million. On average, sell-side analysts forecast that Lexicon Pharmaceuticals will post -2.18 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in LXRX. Commonwealth Equity Services LLC grew its position in shares of Lexicon Pharmaceuticals by 40.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 4,746 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at approximately $202,000. State Street Corp grew its position in shares of Lexicon Pharmaceuticals by 1.5% during the 3rd quarter. State Street Corp now owns 952,606 shares of the biopharmaceutical company’s stock valued at $2,867,000 after acquiring an additional 13,654 shares during the period. Pictet Asset Management Ltd. grew its position in shares of Lexicon Pharmaceuticals by 9.6% during the 3rd quarter. Pictet Asset Management Ltd. now owns 729,876 shares of the biopharmaceutical company’s stock valued at $2,197,000 after acquiring an additional 64,100 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at approximately $1,590,000.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: What is the Dow Jones Industrial Average (DJIA)?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.